Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
Anand Prakash Singh, Prachi Umbarkar, Sultan Tousif, Hind Lal
Topics & Concepts
PonatinibMedicineCardiotoxicityDasatinibBosutinibNilotinibImatinibTyrosine kinaseTyrosine-kinase inhibitorMyeloid leukemiaPharmacologyOncologyInternal medicineCancerChemotherapyReceptorChronic Myeloid Leukemia TreatmentsChemotherapy-induced cardiotoxicity and mitigationEosinophilic Disorders and Syndromes